Characterization of Alzheimer's tau biomarker discordance using plasma, CSF, and PET.

Yu GuoYu-Yuan HuangXue-Ning ShenShi-Dong ChenHao HuZuo-Teng WangLan TanJin-Tai Yunull null

Published in: Alzheimer's research & therapy (2021)

Our results indicate that plasma and CSF p-tau181 abnormalities associated with amyloidosis occur simultaneously in the progression of AD pathogenesis and related cognitive decline, before tau-PET turns positive.

Keyphrases

cognitive decline
cerebrospinal fluid
mild cognitive impairment
pet ct
computed tomography
positron emission tomography
pet imaging